secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003076
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma receives FDA EOP2 support for AP-SA02 Phase 3 in S. aureus bacteremia
--------------------------------------------------------------------------------

- FDA confirmed Phase 2a diSArm data support advancement of AP-SA02 to a Phase 3 superiority study.
- Phase 3 study anticipated to initiate in the second half of 2026 in complicated S. aureus bacteremia.
- First bacteriophage company to advance a clinical candidate to Phase 3 for this indication.
- FDA is amenable to a request for Qualified Infectious Disease Product (QIDP) designation; Armata has submitted the request.
- Partnership with U.S. Department of Defense and significant shareholder Innoviva continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926003076/0001104659-26-003076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926003076/tm262898d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer